Our results confirm that CD200 is a valuable marker in confirming the diagnosis of CLL and HCL, adding CD200 to the routine testing panel will aid in differentiating between CLL and MCL in cases with overlapping immunophenotyping results. This evidence concerns the gene CD200 and B-cell chronic lymphocytic leukemia.